Market Overview:

According to IMARC Group’s latest research publication, “Peripheral Artery Disease Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2026-2034”, The global peripheral artery disease market size was valued at USD 5.1 Billion in 2025. The market is projected to reach USD 7.9 Billion by 2034, exhibiting a CAGR of 4.78% from 2026-2034.

This detailed analysis primarily encompasses industry size, business trends, market share, key growth factors, and regional forecasts. The report offers a comprehensive overview and integrates research findings, market assessments, and data from different sources. It also includes pivotal market dynamics like drivers and challenges, while also highlighting growth opportunities, financial insights, technological improvements, emerging trends, and innovations. Besides this, the report provides regional market evaluation, along with a competitive landscape analysis.

How AI and Innovation Are Reshaping the Peripheral Artery Disease Market

• AI-powered vascular imaging and diagnostic platforms are enhancing clinical decision-making in peripheral artery disease care, enabling more precise detection and early-stage identification in outpatient and hospital settings across the United States.
• Peripheral artery disease impacts over 200 million individuals globally, affecting 10% to 15% of adults aged over 50, underscoring the massive unmet need for scalable and accessible treatment solutions.
• North America leads the global market with a 39.1% share in 2025, underpinned by a robust healthcare infrastructure comprising 6,093 hospitals across the United States as of early 2025.
• In March 2025, Shockwave Medical’s Javelin intravascular lithotripsy catheter was introduced in the US, demonstrating a 99% procedural success rate in clinical trials for addressing severe peripheral artery disease.
• Between 2025 and 2050, crude cardiovascular mortality in Asia is projected to increase by 91.2%, pushing governments and health systems to accelerate early screening and disease management programs across the region.

Download a sample PDF of this report: https://www.imarcgroup.com/peripheral-artery-disease-market/requestsample

Key Trends in the Peripheral Artery Disease Market

• Technological Advancements in Minimally Invasive Surgeries: New catheter-based devices, including drug-coated balloons, advanced angioplasty systems, atherectomy devices, and specialized stents, are expanding treatment options for peripheral artery disease patients. These technologies reduce patient discomfort, shorten hospital stays, and enable faster recovery while preserving natural vascular anatomy. In May 2025, UC Davis Health became the first hospital in the Sacramento area to implement the DETOUR System for percutaneous transmural arterial bypass, offering an innovative alternative to open bypass surgery by redirecting blood circulation through the femoral vein and significantly reducing complications.
• Rising Prevalence of Lifestyle-Related Risk Factors: Diabetes, obesity, hypertension, and smoking are major contributors to peripheral artery disease development. Individuals with diabetes are 3 to 4 times more prone to developing peripheral artery disease, as the condition leads to atherosclerosis that narrows arteries and restricts blood flow. Rising global obesity rates, particularly as adult obesity in the US grew by 13.6% between 2010 and 2024, are intensifying demand for diagnostic tools and interventional treatments such as angioplasty, stenting, and bypass surgery.
• Expanding Aging Population Globally: The worldwide population of individuals aged 60 and above is projected to reach 1.4 billion by 2030. As people age, arteries naturally lose elasticity, increasing the risk of peripheral artery disease. This demographic shift is driving demand for vascular diagnostics, preventive treatments, and minimally invasive interventions. In Europe, by 2050, 40.6% of the EU-27 population will be aged 55 or older, creating a substantial and growing patient base for peripheral artery disease care.
• Adoption of GLP-1 Receptor Agonists Beyond Diabetes: Research presented at the Society for Vascular Surgery’s VAM25 in June 2025 indicated that GLP-1 receptor agonists significantly reduced major cardiovascular and limb consequences in patients with moderate peripheral artery disease, including lower rates of heart attacks, amputations, and hospitalizations. The March 2025 STRIDE trial showed semaglutide delivered a 13% improvement in walking distance and a 54% reduction in the risk of death or revascularization for peripheral artery disease patients with type 2 diabetes.
• Growth of Home Care Settings and Outpatient Facilities: Patients are increasingly opting for specialty clinics and outpatient facilities for peripheral artery disease management, drawn by faster service, shorter wait times, and specialized vascular expertise. Investment in outpatient vascular care centers is growing, particularly in North America, supported by digital health tools, wearable monitoring devices, and telemedicine platforms that enable continuous patient tracking without requiring hospital visits.

Growth Factors in the Peripheral Artery Disease Market

• High Burden of Chronic Disease Among Populations: Six out of every ten Americans live with at least one chronic illness, while four out of ten face two or more concurrent conditions, creating a large and complex patient population at elevated risk for peripheral artery disease. This reality is accelerating government focus on early cardiovascular screening programs and driving up procedural volumes across hospitals and specialty clinics.
• Advancements in Drug Therapies and Medical Devices: Peripheral stents, holding a 22.8% share of the type segment in 2025, are central to restoring blood flow in narrowed or blocked peripheral arteries. Drug-eluting stents and bioresorbable materials are improving long-term patency rates and reducing repeat procedures. In March 2025, Lupin released generic rivaroxaban 2.5 mg tablets in the US after receiving final regulatory approval, providing a more affordable option for lowering cardiovascular risks in individuals with peripheral artery disease and coronary artery disease.
• Increased Healthcare Spending and Infrastructure Investments: Brazil’s Unified Health System funding was set to increase by 6.2% relative to 2024, reflecting heightened national investment in both preventive and interventional cardiovascular services across Latin America. Similarly, in the Middle East, Saudi Arabia’s population aged 60 and above stands at 5% in 2025 and is expected to rise considerably by 2040, prompting governments to expand vascular care infrastructure and community outreach programs.
• Rising Clinical Research Activity and Trial Participation: The BD XTRACT Registry launched in May 2025 plans to enroll up to 600 patients across 100 locations in the US to evaluate the Rotarex Atherectomy System at 30 days, 6 months, and 12 months post-procedure, reflecting a strong industry commitment to building real-world evidence for peripheral artery disease treatments. Cross-border research collaborations within the European Union are also promoting innovation tailored to diverse patient populations.
• Integration of Digital and Point-of-Care Technologies: Mobile telemedicine units, AI-oriented vascular screening tools, and point-of-care testing devices in rural clinics are enhancing early detection and patient outreach in underserved regions across Asia Pacific and the Middle East and Africa. Regional production of cost-effective stents and catheters is further supporting broader adoption of endovascular procedures across tier II and tier III cities, making advanced peripheral artery disease care more accessible and equitable.

Get Instant Access to the Full Report with a Special Discount!

Leading Companies Operating in the Global Peripheral Artery Disease Industry:

• Abbott Laboratories
• AngioDynamics
• B. Braun Melsungen AG
• Becton Dickinson and Company
• Biotronik SE and Co. KG
• Boston Scientific Corporation
• Cardinal Health Inc.
• Cook Medical LLC
• Koninklijke Philips N.V.
• Medtronic plc
• Terumo Corporation

Peripheral Artery Disease Market Report Segmentation:

Breakup By Type:

• Peripheral Angioplasty Balloons
• Peripheral Stents
• Peripheral Catheters
• Inferior Vena Cava (IVC) Filters
• Plaque Modification Devices
• Hemodynamic Flow Alteration Devices
• Peripheral Accessories

Peripheral stents hold 22.8% of the type segment in 2025 on account of their effectiveness in treating claudication and critical limb ischemia through minimally invasive procedures, their ability to prevent artery collapse post-angioplasty, and the growing adoption of drug-eluting and bioresorbable stent technologies.

Breakup By End User:

• Hospitals
• Specialty Clinics
• Others

Hospitals account for the dominant share in the market due to their ability to provide comprehensive diagnostic imaging, complex surgical interventions such as stent placements and bypass surgeries, continuous monitoring, and emergency vascular care under one roof with specialized medical professionals.

Breakup By Region:

• North America (United States, Canada)
• Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
• Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
• Latin America (Brazil, Mexico, Others)
• Middle East and Africa

North America enjoys the leading position in the peripheral artery disease market, accounting for a share of 39.1% in 2025, owing to a high prevalence of lifestyle-related risk factors, a well-established healthcare network of over 6,093 hospitals, advanced treatment technologies, strong reimbursement policies, and continuous investment by key industry players in research, development, and awareness campaigns.

Recent News and Developments in the Peripheral Artery Disease Market

• March 2025: Findings from the STRIDE trial revealed that semaglutide notably enhanced walking distance, symptoms, and quality of life for peripheral artery disease patients with type 2 diabetes, showing a 13% improvement in walking distance and a 54% reduction in the risk of death or requirement for revascularization.
• March 2025: Johnson and Johnson’s Shockwave Medical introduced the Javelin intravascular lithotripsy catheter in the US, designed to transmit sonic energy from its tip to penetrate difficult arterial obstructions, demonstrating a 99% procedural success rate with minimal complication rates in clinical trials.
• May 2025: BD (Becton, Dickinson and Company) revealed the initiation of the XTRACT Registry, a real-world study assessing the Rotarex Atherectomy System for peripheral artery disease, aiming to enroll up to 600 patients at 100 US locations with follow-up assessments at 30 days, 6 months, and 12 months post-procedure.
• May 2025: UC Davis Health became the first hospital in the Sacramento area to implement the DETOUR System for percutaneous transmural arterial bypass, offering a minimally invasive substitute for open bypass surgery by redirecting blood circulation through the femoral vein and reducing complications and recovery duration.
• June 2025: Research presented at the Society for Vascular Surgery’s VAM25 indicated that GLP-1 receptor agonists significantly reduced major negative cardiovascular and limb consequences in individuals with moderate peripheral artery disease, with patients experiencing lower rates of heart attacks, amputations, and hospital stays, advocating for expanded application of these medications in peripheral artery disease management beyond diabetes treatment.

Note: If you require specific details, data, or insights that are not currently included in the scope of this report, we are happy to accommodate your request. As part of our customization service, we will gather and provide the additional information you need, tailored to your specific requirements. Please let us know your exact needs, and we will ensure the report is updated accordingly to meet your expectations.

About Us:

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provides a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Contact Us:

IMARC Group

134 N 4th St. Brooklyn, NY 11249, USA

Email: sales@imarcgroup.com

Tel No: (D) +91 120 433 0800

United States: +1-201-971-6302